These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 19217205

  • 1. Epidermal growth factor receptor vIII enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma.
    Wang H, Jiang H, Zhou M, Xu Z, Liu S, Shi B, Yao X, Yao M, Gu J, Li Z.
    Cancer Lett; 2009 Jun 28; 279(1):30-8. PubMed ID: 19217205
    [Abstract] [Full Text] [Related]

  • 2. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Jiang H, Dong Q, Luo X, Shi B, Wang H, Gao H, Kong J, Zhang J, Li Z.
    Cancer Lett; 2014 Jan 01; 342(1):113-20. PubMed ID: 24007863
    [Abstract] [Full Text] [Related]

  • 3. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
    Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME.
    Cancer Res; 2000 Jun 01; 60(11):3081-7. PubMed ID: 10850460
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
    Lammering G, Hewit TH, Holmes M, Valerie K, Hawkins W, Lin PS, Mikkelsen RB, Schmidt-Ullrich RK.
    Clin Cancer Res; 2004 Oct 01; 10(19):6732-43. PubMed ID: 15475464
    [Abstract] [Full Text] [Related]

  • 5. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR.
    Clin Cancer Res; 2006 Sep 01; 12(17):5064-73. PubMed ID: 16951222
    [Abstract] [Full Text] [Related]

  • 6. [Establishment of a multidrug-resistant cell line BEL-7402/5-FU of human hepatocellular carcinoma and its biological characteristics].
    Gu W, Zhang YN, Li B, Han J, Cheng BB, Ling CQ.
    Zhong Xi Yi Jie He Xue Bao; 2006 May 01; 4(3):265-70. PubMed ID: 16696913
    [Abstract] [Full Text] [Related]

  • 7. TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU.
    Zhao J, Zhang X, Shi M, Xu H, Jin J, Ni H, Yang S, Dai J, Wu M, Guo Y.
    Hepatology; 2006 Jul 01; 44(1):205-15. PubMed ID: 16799960
    [Abstract] [Full Text] [Related]

  • 8. Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo.
    Kojiro S, Yano H, Ogasawara S, Momosaki S, Takemoto Y, Nishida N, Kojiro M.
    J Gastroenterol Hepatol; 2006 Jan 01; 21(1 Pt 1):129-37. PubMed ID: 16706824
    [Abstract] [Full Text] [Related]

  • 9. RASSF1A expression inhibits the growth of hepatocellular carcinoma from Qidong County.
    Xue WJ, Li C, Zhou XJ, Guan HG, Qin L, Li P, Wang ZW, Qian HX.
    J Gastroenterol Hepatol; 2008 Sep 01; 23(9):1448-58. PubMed ID: 17683489
    [Abstract] [Full Text] [Related]

  • 10. Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance.
    Weppler SA, Li Y, Dubois L, Lieuwes N, Jutten B, Lambin P, Wouters BG, Lammering G.
    Radiother Oncol; 2007 Jun 01; 83(3):333-9. PubMed ID: 17512071
    [Abstract] [Full Text] [Related]

  • 11. MEL-pep, an analog of melittin, disrupts cell membranes and reverses 5-fluorouracil resistance in human hepatocellular carcinoma cells.
    Ke M, Dong J, Wang Y, Zhang J, Zhang M, Wu Z, Lv Y, Wu R.
    Int J Biochem Cell Biol; 2018 Aug 01; 101():39-48. PubMed ID: 29800725
    [Abstract] [Full Text] [Related]

  • 12. Opsin3 sensitizes hepatocellular carcinoma cells to 5-fluorouracil treatment by regulating the apoptotic pathway.
    Jiao J, Hong S, Zhang J, Ma L, Sun Y, Zhang D, Shen B, Zhu C.
    Cancer Lett; 2012 Jul 01; 320(1):96-103. PubMed ID: 22313545
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of invasion and metastasis of hepatocellular carcinoma cells via targeting RhoC in vitro and in vivo.
    Wang W, Wu F, Fang F, Tao Y, Yang L.
    Clin Cancer Res; 2008 Nov 01; 14(21):6804-12. PubMed ID: 18980974
    [Abstract] [Full Text] [Related]

  • 14. Role of growth factor receptor bound protein 7 in hepatocellular carcinoma.
    Itoh S, Taketomi A, Tanaka S, Harimoto N, Yamashita Y, Aishima S, Maeda T, Shirabe K, Shimada M, Maehara Y.
    Mol Cancer Res; 2007 Jul 01; 5(7):667-73. PubMed ID: 17634422
    [Abstract] [Full Text] [Related]

  • 15. The effect of calmodulin antagonist berbaminederivative-EBB on hepatoma in vitro and in vivo.
    Liu J, Qi S, Zhu H, Zhang J, Li Z, Wang T.
    Chin Med J (Engl); 2002 May 01; 115(5):759-62. PubMed ID: 12133551
    [Abstract] [Full Text] [Related]

  • 16. Combining siRNAs at two different sites in the EGFR to suppress its expression, induce apoptosis, and enhance 5-fluorouracil sensitivity of colon cancer cells.
    Wu X, Deng Y, Wang G, Tao K.
    J Surg Res; 2007 Mar 01; 138(1):56-63. PubMed ID: 17169374
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.
    Ischenko I, Camaj P, Seeliger H, Kleespies A, Guba M, De Toni EN, Schwarz B, Graeb C, Eichhorn ME, Jauch KW, Bruns CJ.
    Oncogene; 2008 Dec 04; 27(57):7212-22. PubMed ID: 18794807
    [Abstract] [Full Text] [Related]

  • 18. Methylation of Ras association domain family protein 1, isoform A correlated with proliferation and drug resistance in hepatocellular carcinoma cell line SMMC-7721.
    Zhao QZ, Dou KF.
    J Gastroenterol Hepatol; 2007 May 04; 22(5):683-9. PubMed ID: 17444856
    [Abstract] [Full Text] [Related]

  • 19. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
    Yanase K, Yoshiji H, Ikenaka Y, Noguchi R, Kitade M, Kaji K, Yoshii J, Namisaki T, Yamazaki M, Asada K, Tsujimoto T, Akahane T, Uemura M, Fukui H.
    Oncol Rep; 2007 Feb 04; 17(2):441-6. PubMed ID: 17203185
    [Abstract] [Full Text] [Related]

  • 20. Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis.
    Zhao QT, Yue SQ, Cui Z, Wang Q, Cui X, Zhai HH, Zhang LH, Dou KF.
    Life Sci; 2007 Jan 09; 80(5):484-92. PubMed ID: 17097688
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.